Other languages Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
6.86 ^USD	+2.54%		-4.06%	+32.95%

May. 28	Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis	MT
May. 28	Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	May. 28
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed	May. 03
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024	May. 02
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 29
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	Apr. 29
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	Apr. 29
GNW-Adhoc: Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt	Apr. 12
Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt	Apr. 12
Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study	Apr. 10
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Extend Gains to Premarket	Apr. 03
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Jump After Hours	Apr. 02
Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	Apr. 02
Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024	Mar. 07
Sight Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Sight Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07
Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting	Feb. 14
Sight Sciences Expects Lower Q4, Higher Full-Year 2023 Revenue	Jan. 08
Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Other languages

Filters